Leaving Valencia after European Association of Urology (EAU) #EAUTalentIncubator module 2. A great opportunity to share experience and knowledge on aspects of wellbeing + how it affects work efficiency, and to learn from Jason Howlett, Nick Raison, Eamonn Rogers. A great program again!@JLVasquez82 EAU Young Urologists

Sabine D. Brookman-May gives insights into strategic use of data collection and interpretation to inspire behavior change and contribute to positive outcomes in performance ⌚️❤️😴 #EAUTalentIncubator 💪🏾🌱 EAU Young Urologists

📬 Finally out in The Lancet Oncology the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in National Comprehensive Cancer Network (NCCN) guidelines. Congrats Ashish M. Kamat, MD, MBBS Petros Grivas & team! sciencedirect.com/science/articl…

Diversity and global representation at its best in the IBCG Amer. Urol. Assn. #AUA -IBCG #Bladderca forum!
Ashish M. Kamat, MD, MBBS Joan Palou Redorta Petros Grivas Janet Kukreja Karima Oualla, MD,MSc Prof Param Mariappan Petros Grivas Chiara Mercinelli Andrea Necchi Philippe spiess

#MoonRISe -1: Phase 3 study of #TAR210 , an erdafitinib intravesical delivery system, vs intravesical chemotherapy in patients with IR #NMIBC with susceptible FGFR alterations. Presentation by Roger Li Moffitt Cancer Center. #AUA24 coverage by Zach Klaassen > bit.ly/3QxXr8F

Getting MoonRISe1 started with Roger Li and Benjamin Pradere on board is the best kick-off and basis for a study on #TAR210 in #FGFR + IR #NIMBC #BladderCancer

Great work Josh Linscott Roger Li presented at #AUA2024
➡️ Mutations detected by #utDNA concordant with bladder tumor
➡️ Range from single point mutations to chromosomal loss/gain
➡️ Possible tool for MRD detection in #NMIBC
Moffitt Cancer Center #BladderCancer

A really great session at #AUA24
Thank you #IBCG Ashish M. Kamat, MD, MBBS for an excellent agenda, great debates and speakers #BladderCancer
Beyond others Arnulf Stenzl Petros Grivas debating the need of RC in cT0 after NAC/NIO
👉biomarkers/ctDNA/MRI may help to select pts, but more evidence needed

Can we settle the debate about #PLND at RC in #BladderCancer ?
✅ Seth Lerner sharing arguments for SLND instead ELND based on S1011 and LEA studies
🚫Sia Daneshmand, M.D. Outcomes might still get improved with extended LND, especially in selected patients (eg ctDNA+)
#AUA24 #IBCG

Excellent talks Sarah P. Psutka MD MS and Prof Param Mariappan on disease management of LG IR #NMIBC
Are #chemoablation , fulguration, #ActiveSurveillance proper options? A risk adapted approach based on rigorous diagnosis and #IBCG risk criteria might be most recommendable #AUA24 #BladderCancer

To do or not to do - Re- #TURBT ? Supporting arguments on both sides Jeremy Teoh and Badrinath Konety, MD, MBA “Do it right the first time” (Jeremy Teoh) or despite that still needed? #BladderCancer

Antoni Vilaseca presenting updated data on #TAR210 FIH study in patients with #FGFR + #NMIBC today at #AUA24
✅90% estimated 12 months RFS in BCG experienced HR NMIBC
✅90% CR in IR NMIBC
#BladderCancer Johnson & Johnson Innovation #MyCompany #Erdafitinib

Updated data from Sunrise1 #TAR200 study presented by Joe Jacob MD, MCR in patients with CIS +/-papillary HR #NMIBC #AUA24
✅ 82.8% Complete Response (CR) rate per central review/86.2% per local assessment
✅ 98% of CRs were achieved within 12 weeks
Johnson & Johnson Innovation #MyCompany #MyTeam

#SethLerner presenting data from #SWOGS1011 on standard vs extended #LND at time of #RadicalCystectomy
👉No benefit for ELND compared to SLND in terms of OS or DFS
👉ELND associated with higher morbidity and peri-operative mortality
#AUA24 #BladderCancer

Comprehensive summary by Todd 〽️ Morgan, MD of updated Amer. Urol. Assn. AUA guidelines on decision making at #BCR after RP #ProstateCancer highlighting the need to consider risk factors and the role of #PSMAPET #AUA24 #SalvageRT

Started #AUA24 with a full day dedicated to AUA Innovation Nexus
Great meeting to initiate exchange between #Pharma , #biotechs and #startups with the focus on urology/medical technology led by an experienced urological entrepreneur Dr. Steven Kaplan Amer. Urol. Assn.

I am not sure I want to get adapted to this style T.C. Boyle
Prefer my old #Porsche 911
And I know - it is not made for day to day rides, just sometimes
But then the sound of a Porsche makes make so happy that I don’t produce any additional #CO2 (beyond breathing) for a while